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INTRODUCTION
Hematopoietic stem cell transplantation provides essen-
tial support for highly aggressive marrow-ablative chemora-
diation therapies and, when followed by transplantation
rescue, are potentially curative. They may nonetheless leave
the patient vulnerable to the following late complications
that threaten long-term survival and well-being: regimen-
related toxicities, immunodeficiencies, infections, chronic
graft-versus-host disease (GVHD), and recurrent or sec-
ondary malignancies that may arise months to years after
transplantation [1]. Regimen-related complications may
include cataract formation, endocrine abnormalities, neuro-
logical deﬁciencies and cognitive impairment, gonadal dys-
function, and gynecological irregularities. Most signiﬁcantly,
33% of related HLA-matched transplant recipients and
50% to 70% of unrelated or related mismatched recipients
will develop chronic GVHD within 18 months of transplan-
tation [2]. The existing research on the late complications of
transplantation clearly indicates that some long-term sur-
vivors continue to have significant, even life-threatening,
health problems [3-8].
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ABSTRACT
Emerging literature suggests that quality of life (QOL) after bone marrow transplantation is relatively good but is
accompanied in some patients by a variety of residual difficulties. The studies supporting this finding, however, have
been somewhat limited in scale, scope, design, and analysis. We comprehensively measured changes in multi-
dimensional QOL in a 4-year longitudinal follow-up of 415 adult patients who received hematopoietic stem cell
transplants at Fred Hutchinson Cancer Research Center. Questionnaire packets containing 271 items were mailed
annually posttransplantation to patients’ homes. Standard methods of analysis yielded conditional estimates depend-
ing on compliance and survival, whereas new, likelihood-based methods generated unconditional estimates applica-
ble to the full intent-to-treat population. Typical QOL levels generally remained high over the entire study period.
Most QOL functioning significantly improved over 4 years, with the remainder showing no important decrement.
Although isolated problem areas, such as sexual dissatisfaction, did emerge, the level of dysfunction for most physi-
cal and psychological scales remained below 30% of scale maxima. Broadly similar results were obtained for condi-
tional estimation, which may contain an optimistic bias, and for unconditional estimation, which largely avoids the
bias. Because concurrence was obtained between the 2 types of estimation, we conclude that most patients really do
experience good levels of QOL in the 4 years after transplantation. Although some problems can be anticipated,
typical patients can look forward to a QOL after transplantation that is broadly comparable to that of the normal
population. 
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Health problems are a subset of a broad domain known
as quality of life (QOL), a designation that has evolved from
an idiosyncratic lay term to a focused research construct
comprising the dimensions of physical, psychological, and
social functioning as well as symptomatology [9-19]. An
emerging research consensus [14,17-37] now characterizes
the QOL of bone marrow transplantation (BMT) survivors
as relatively good and tending to improve with time post-
transplantation, but with a variety of residual difﬁculties in
some patients [38]. For example, in a cross-sectional assess-
ment of 135 marrow graft recipients who were 6 months to
12 years (mean 4 years) post-BMT, Baker et al. [24] found a
high level of perceived QOL, with low tension, fatigue, con-
fusion, and depression. Hengeveld et al. [25] found that
about half of survivors who were from 1 to 5 years posttrans-
plantation reported problems related to physical complica-
tions, sexual problems, infertility, and inability to work.
However, most showed surprisingly good affective adjust-
ment and were highly positive in their outlook. Chao et al.
[26] reported that 88% of surviving adult patients perceived
an above-average to excellent QOL 1 year after autologous
BMT, and Wingard et al. [27] showed similarly good to
excellent health and functional ability 4 years after transplan-
tation. Wolcott et al. [29] examined 26 adults who were an
average of 42 months post-BMT. Although three quarters of
the sample appeared to be doing well, the remaining 25%
reported ongoing medical problems, and 15% to 25%
reported signiﬁcant emotional distress, low self-esteem, and
a less-than-optimal life satisfaction. Molassiotis et al. [34]
found that most long-term BMT survivors had excellent
QOL and in some cases showed better adjustment than
matched patients receiving maintenance chemotherapy.
However, a signiﬁcant number showed depression and anxi-
ety, and one ﬁfth had not returned to full-time employment
more than 3 years after their transplantations. Kopp et al.
[39] reported that QOL was signiﬁcantly better in a group of
BMT patients surviving an average of 5 years after transplan-
tation than in a second group at less than 1 year after BMT.
Two recent studies compared QOL in BMT patients
with population norms. Hann et al. [17] found that 3-year
survivors of BMT for breast cancer reported significantly
impaired physical, role, emotional, and social functioning
and poorer health than women with no cancer history.
Sutherland et al. [32] showed that, of 231 BMT survivors,
those less than 3 years from transplantation experienced
diminished QOL compared with general population norms
but that those surviving beyond that point were indistin-
guishable from the normal population in most QOL
domains and significantly better in some psychological
aspects of health. In a major multicenter cross-sectional
study of 200 BMT recipients, Andrykowski et al. [21]
reported evidence that functional status improved with time
after BMT, but that greater age at transplantation, lower
education level, and more advanced disease before trans-
plantation predicted poorer QOL. Although many patients
in this study reported normal QOL, the majority believed
that their QOL was worse than it was before they got sick.
The authors assessed the QOL of 125 adult patients
surviving a mean of 10 years (range, 6-18 years) after BMT,
using a detailed and wide-ranging battery of tests [35,36].
Seventy-four percent of long-term survivors of transplanta-
tion reported that their current QOL was the same or better
than before transplantation; 80% rated their current health
status and QOL as good to excellent; and 88% said the
beneﬁts of transplantation outweighed the side effects. Ten
years or more after transplantation, long-term survivors
continued to experience a moderate incidence of lingering
complications and demands, including emotional and sexual
dysfunction, fatigue, eye problems, sleep disturbance, gen-
eral pain, and cognitive dysfunction. However, the severity
or degree of distress attributed to those complications was,
for most survivors, consistently low. Only 5% rated both
their QOL and health status as poor. Long-term survivors
demonstrated good mood and low psychological distress
compared with cancer and population norms. The most fre-
quently cited demand of recovery was the perceived lack of
social support as time went on.
Prospective/Longitudinal Studies
All of the above studies were cross-sectional in design
and often retrospective. It is difficult, therefore, to draw
strong conclusions from them about the broad impact of
BMT on QOL and how it may change. A number of
researchers have emphasized the need for more large-scale,
prospective, longitudinal assessments of the relationship
between BMT and subsequent QOL [14,20,30,33,37]. To
date, very few have met that challenge. Zittoun et al. [30]
prospectively compared QOL among patients recovering
from conventional chemotherapy, autologous BMT, and
allogeneic BMT. They demonstrated a uniformly poorer
QOL after allogeneic BMT than after autologous BMT,
which in turn was poorer than QOL after chemotherapy.
Hjermstad et al. [37] found differences in QOL between
autologous and allogeneic stem cell transplantation candi-
dates before transplantation that were much less pronounced
1 year after transplantation. Syrjala et al. [28] found that the
large majority of 67 long-term BMT survivors returned to
full-time employment with normal pretransplantation levels
of functioning in most areas, although recovery took longer
than 1 year for 40%. McQuellon et al. [33] compared the
QOL of 24 patients before and after receiving autologous
transplants for breast cancer and found very little difference.
QOL and mood improved slightly after BMT. Similarly,
Andrykowski et al. [20] prospectively assessed the physical
and psychological status of 28 BMT patients and showed few
signiﬁcant differences between pre- and post-BMT.
Longitudinal follow-up is necessary, but not sufﬁcient,
for accurately inferring change. The prospective studies
described above featured small sample sizes and/or relatively
short follow-ups. To describe long-term recovery from
BMT and the permanency of changes in QOL, longer
repeated follow-up assessments with large patient cohorts
are necessary, but still not sufﬁcient. A diverse literature [40-
43] reﬂects recognition that complex sources of attrition in
QOL studies typically yield longitudinal samples that may
not be representative of the original baseline sample and
that valid analysis must acknowledge this limitation: surviv-
ing subsamples with complete longitudinal data almost
certainly yield biased estimates of QOL. Precision of
description demands large sample sizes, but accuracy of
inference requires methods that generalize to the target
population, not just the surviving subsample.
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Present Study
This study is a large-scale, prospective longitudinal
investigation of QOL in adult hematopoietic stem cell
transplantation (henceforth referred to as BMT) recipients.
We have used the same wide-ranging and validated meas-
ures as in our earlier cross-sectional project [35,36], but we
have expanded the scope of the study to evaluate the multi-
dimensional course of QOL at years 1, 2, 3, and 4 post-
BMT. We also have incorporated an analysis method that
allows for much broader generalization and yields narrower
conﬁdence intervals for population estimates than methods
used in previous studies.
MATERIALS AND METHODS
Setting and Sample
The study was conducted from 1994 to 1998 at the Fred
Hutchinson Cancer Research Center (FHCRC) in Seattle,
Washington. Protocols were approved by the institutional
review board of FHCRC. Eligible patients were (1) aged
≥18 years at time of transplantation; (2) able to read, write, and
understand English; (3) currently residing in the United States
or Canada; and (4) not in relapse or suffering persistent disease
at any post-BMT assessment point. All types of hematopoietic
transplantation and treatment regimens were acceptable.
After the 1-year anniversaries of their transplantations, a
total of 679 eligible candidates were identified during the
project period as eligible for participation. Of these, 415
(48% male, 52% female) were located, agreed to participate,
and completed the questionnaires. Of the 415 who com-
pleted and returned the questionnaires, 3 refused or with-
drew from further assessments and 6 died shortly after the
ﬁrst mail-out; 19 respondents relapsed after returning their
questionnaires and were withdrawn from subsequent assess-
ments. Sample sizes at subsequent annual assessments (years
2-5) were 217, 117, 35, and 6 patients, respectively. Declin-
ing sample sizes with each year posttransplantation reﬂects
actual attrition, loss to follow-up, and ongoing accrual of
newer patients for whom longitudinal assessments have
been scheduled but not yet collected. Because the number of
cases accumulated at the fifth year was still quite small at
time of analysis, results will be restricted to assessment years
1 through 4. Table 1 displays the accrual, attrition, and
yearly scale responses for both continuing and terminating
patients over 4 study years.
Questionnaire Measures
We selected 7 self-report instruments that had shown
good reliability and validity in our previous study [35,36] to
provide as comprehensive an assessment as possible, mini-
mally encompassing the 4 domains of QOL deﬁned above
and allowing respondents to provide extensive additional
quantitative and qualitative information. Patients completed
the same battery at all assessment points. Instruments
included the following.
Biodemographics. This instrument includes 26 items on
income, employment, and health insurance and expenses,
as well as standard questions about age, religion, marital
status, etc.
EORTC QLQ-C30. The EORTC (European Organiza-
tion for Research and Treatment of Cancer) QLQ-C30
[30,44-46] is a 30-item core or generic QOL tool for use
with cancer patients, to which disease-speciﬁc modules, such
as the BMT-specific instrument described below, must be
appended [47,48]. The QLQ-C30 indexes 6 multi-item
scales of functioning: Physical Functioning, Role Function-
ing, Emotional Functioning, Cognitive Functioning, Social
Functioning, and Global Health Status/QOL. It further
measures 9 multi-item scales or single items of symptomatol-
ogy/problems: Fatigue, Nausea and Vomiting, Pain, Dysp-
nea, Constipation, Diarrhea, Sleep Disturbance, Appetite
Loss, and Financial Impact. Items are scaled on a yes or no
basis or on 4-point Likert-type scales where 1 = not at all,
2 = a little bit, 3 = quite a bit, and 4 = very much. Global
Physical Condition and Global QOL are assessed by two
7-point Likert scales. All multi-item scales and single-item
measures cited in this study have been linearly transformed
to standard 0-to-100 scales, with higher scores representing
poorer functioning or higher levels of symptomatology. The
QLQ-C30 has been extensively tested and has shown good
reliability and validity [39,47,49-58].
Late Complications of BMT Module. The Late Complica-
tions of BMT Module is a BMT-speciﬁc module/addendum
to the EORTC QLQ-C30 developed by the authors to supple-
ment the QLQ-C30 generic measure by evaluating symptoms
speciﬁc to BMT but not covered (or covered insufﬁciently) in
the core questionnaire, as suggested by EORTC guidelines
[47]. Original content validity for the 50 items was derived
from in-service discussions with FHCRC staff and from the
literature [2,4-8]. The items, scaled identically to the EORTC
QLQ-C30 with 4-point Likert scales linearly transformed to
Table 1. Accrual, Attrition, and Scale Responses Over 4 Annual Assessments*
Year Posttransplantation
1 2 3 4
Overall Scale Response Overall Scale Response Overall Scale Response Overall Scale Response
In study at start of year 415 — 387 — 217 — 117 —
Due for assessment in year 415 — 340 — 169 — 81 —
Relapsed/died 25 25 30 6 12 3 4 0
Lost to follow-up 3 3 93 2 40 1 42 0
Total attrition (all sources) 28 28 123 8 52 4 46 —
In study end of year 387 387 217 211 117 115 35 34
Total scale responses — 415 — 219 — 112 — 34
*Data are number of patients.
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0-to-100 scales, are rated for occurrence/severity of
symptoms. Multiple items are categorized by Skin, Eyes,
Mouth/Throat, Joints/Muscles Involvement, Pulmonary
Problems, Sex/Warmth/Intimacy, Cognitive Dysfunction,
Infections, and Fear of Relapse/Dying. When calculating
composite scores, items from 2 categories, Pulmonary Prob-
lems and Cognitive Dysfunction, were combined with items
from the EORTC QLQ-C30 to form more complete BMT-
specific subscales. Single items index physical appearance,
physical problems with sex, hair and nail loss, teeth problems,
abnormal sense of taste, heartburn, abdominal pain, weight
loss, sinusitis, chronic GVHD, and minor symptoms/ailments. 
Demands of BMT Recovery Inventory. The 59-item
Demands of BMT Recovery Inventory (DBMT) is an adap-
tation of the Demands of Illness Inventory [59]. It quantiﬁes
the number and intensity of demands or hardships associ-
ated with long-term recovery across 5 dimensions: Personal
Meaning, Social Relationships, Self-Image, Monitoring
Symptoms, and Treatment Issues. Items are scored on a
5-point Likert-type scale (0 = not at all, 1 = a little bit,
2 = moderately, 3 = quite a bit, 4 = extremely), with higher
scores signifying greater intensity of demands. 
Proﬁle of Mood States. The 65-item Proﬁle of Mood States
(POMS) [60] measures mood disturbance and the psychologi-
cal distress domain of QOL along 6 dimensions: Tension-
Anxiety, Depression-Dejection, Anger-Hostility, Vigor-
Activity, Fatigue-Inertia, Confusion-Bewilderment, and an
Overall Mood rating. Items are scored on a 5-point (0-4) scale
where 0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit,
and 4 = extremely. The total score ranges from 0 to 260, with
a higher score indicating greater mood disturbance or psycho-
logical distress. The POMS has been widely used in health
research and demonstrates excellent reliability and validity.
Ware Health Perceptions Questionnaire. The Ware Health
Perceptions Questionnaire (WHPQ) [61,62] contains 32 items
measuring 6 dimensions: Current Health, the extent to which
the respondent presently sees himself/herself as being healthy
or ill; Prior Health, whether the respondent perceives a favor-
able (healthy) or unfavorable (unhealthy) prior health history;
Health Outlook, the respondent’s prediction of things to come;
Health Worry/Concern, the extent to which the person is wor-
ried or concerned about his/her state of health; Resistance-
Susceptibility, perception of the ability to resist illness; and
Rejection of Sick Role, characteristic reaction to illness. Items
are scored on a 5-point (1-5) Likert-type scale, where 1 = deﬁ-
nitely false, 2 = mostly false, 3 = don’t know, 4 = mostly true,
and 5 = deﬁnitely true. Higher subscale scores indicate a more
positive perception of health. Reliability and validity of the
WHPQ have been previously well established [61]. 
Long-Term BMT Recovery Questionnaire. The Long-term
BMT Recovery Questionnaire [36] is a 9-item open-ended
questionnaire devised by the authors to elicit information on
reestablishment of daily life after BMT, demands of recov-
ery, coping strategies, limitations imposed by BMT, current
health problems, QOL, and concerns about the future. This
tool provides an abundance of rich qualitative information,
but these data are not described in this report.
Procedures
A packet of questionnaires was mailed to the home of
each potential study participant after the ﬁrst anniversary of
his/her BMT and annually thereafter, for as long as the indi-
vidual chose to participate. In each mailed packet, an accom-
panying cover letter described the study in detail and
included all elements of implied consent to participate in the
study. Completion and return of the packet implied consent
to participate in the study. Each packet also included a
preprinted postcard, the return of which indicated a prefer-
ence to discontinue. Participants failing to respond within
2 months of mailing received a follow-up phone call from a
study nurse. Demographic, disease, and treatment informa-
tion was abstracted from FHCRC medical records.
Statistical Analyses
Measurement Considerations. Traditional medical out-
comes, such as survival and relapse, have self-evident valid-
ity. In contrast, the validity of QOL outcomes depends on
measurement properties of the scales chosen to assess this
complex construct. A necessary condition for validity is that
scales demonstrate adequate reliability or reproducibility.
Reliability was documented in this study with Cronbach’s 
coefficient, a conventional psychometric measure of the
internal consistency of a scale—ie, the extent to which an
overall scale score reflects agreement among individual
items composing the scale. The theoretical range of Cron-
bach’s  is from 0, denoting no internal consistency, to 1.00,
indicating perfect internal consistency. In practice, reliabili-
ties limit the maximum correlations one can detect and
should therefore be in excess of 0.7 when moderate-to-high
correlations are anticipated. Conversely, 2 scales that corre-
late to the extent of their reliabilities provide no indepen-
dent measurement at all. Ideally, reliabilities should be high
and should exceed the intercorrelations among scales.
Data Analysis. The primary goal of our statistical analyses
is the accurate estimation of mean multidimensional QOL at
years 1, 2, 3, and 4 posttransplantation. This apparently sim-
ple goal is difﬁcult to achieve because the 4-year follow-up
period introduces inconsistencies in the sample composition
over time; the combined effects of attrition and new accrual
imply that relatively few patients will be observed at all
assessment points and that these patients will probably not
be representative. Accordingly, our analyses include an
approach that, under mild assumptions, allows broad uncon-
ditional inference for the original baseline population. These
estimates forecast, in an intent-to-treat sense, the mean
QOL of new patients irrespective of their eventual survival
and compliance. For descriptive purposes, we also provide
summary statistics based on all available cases at each occa-
sion; these summary statistics represent narrow estimates of
QOL conditional on survival and study compliance.
Conditional analyses summarized all available patients’
QOL reports at each measurement occasion. Scale and sub-
scale scores were calculated as weighted sums of individual
items according to guidelines published for each questionnaire
and summarized above. When >25% of the items composing a
scale were missing, the scale score was designated as missing.
Missing data also arose sporadically when respondents failed
to complete individual questionnaires, so sample sizes
reported in the tables vary slightly across outcomes. To
enhance interpretability, some scores were linearly trans-
formed to 0 to 100 scales or to item mean scales; such trans-
formations have no effect on statistical analysis and inference.
N.E. Bush et al.
580
To aid in clinical interpretation, in some instances we also cal-
culated a frequency measure describing the percentage of
respondents reporting the existence of a problem or symptom.
The t statistic was used to test that 2 means were equal
or that a coefﬁcient was 0; when there were >2 groups or
classifications, the analysis of variance F statistic was pro-
vided. These inferential statistics are accompanied by effect
size statistics that describe magnitudes of effects. The effect
size, expressed here as proportion of variance accounted for,
provides a pragmatic assessment of the importance of the
observed result that is independent of statistical signiﬁcance.
Higher effect sizes suggest important differences; a propor-
tion of variance (PV) of 10%, for example, would indicate
that the tested effect explains 10% of the variance of the
outcome. For tests of group differences, PVs <5% are gen-
erally considered small; PVs between 5% and 10% are mod-
erate; and PVs >10% are large and likely to be of clinical
importance. PVs for correlations are simply the squares of
the correlation coefﬁcients; in this context, the above guide-
lines for interpreting effect sizes should be roughly doubled.
Probability values unadjusted for multiple comparisons
were reported, even though the numerous tests conducted
increased the cumulative risk of type I errors. This risk is
acceptable because, consistent with our descriptive emphasis
on the magnitudes of effects, we make no claim that statisti-
cally signiﬁcant results denote clinical importance.
Unconditional analyses allow inference to the full intent-
to-treat population by means of a likelihood criterion
imposed on a simple, unrestricted model: for each QOL out-
come y, yit  (t  j bj xij, ) for patient i at assessment
time t incorporating prognostic factors X j. Apart from the
usual assumption of multivariate normality required for sig-
nificance tests, no additional specifications were imposed.
Although the general model allows the number of assessment
points to vary across patients, our data displayed a monotone
pattern of missingness that confers additional protection
against potential missing data bias. This pattern is illustrated
in Figure 1 with the pain symptoms measure from the core
EORTC QLQ-C30. Note that the data are partitioned into
mutually exclusive subsamples deﬁned by time in study and
reason for study termination: patients belong to one and only
one subsample. With monotonically missing longitudinal
data, later observations are present only if earlier observa-
tions are present (ie, all missing data are right-censored). Lit-
tle and Rubin [63] have shown that likelihood models that
condition on prior data having this monotone pattern pro-
vide correct estimates even when the probability of missing
data depends on the values of observed (ie, past) data, an
assumption that is much easier to meet than the stronger
assumption of simple random sampling required for standard
methods. As Figure 1 suggests, subsamples with more com-
plete data may not be representative of other subsamples;
those patients with worsening QOL may well drop out of the
study, leaving remnants with more complete, but positively
biased, scores. The model-based approach greatly minimizes
the impact of this kind of missing data, because it incorpo-
rates correlational relationships as well as all available data at
each time point; we emphasize that it may yield estimates
that differ from those obtained by analyzing only patients
with complete longitudinal data (corresponding to an analy-
sis of the lower right panel of Figure 1). In the event of dis-
agreement, the unconditional estimates would provide more
secure population inference, because they offer protection
against a much wider range of possible missing data mecha-
nisms. The models were implemented using SAS Proc
Mixed (SAS/STAT Software; SAS Institute, Cary, NC), with
detailed speciﬁcations of the statistical models and analysis
sequences available from G.W.D. by request.
The unconditional analyses generated estimates of pop-
ulation means and standard errors at each of the 4 assess-
ment points for each of the QOL variables, adjusted for the
effects of possible prognostic factors. The analyses followed
a standard sequence. In the ﬁrst model for each QOL out-
come, the following 7 prognostic factors were entered as
predictors: broad diagnosis, transplant type (autologous ver-
sus allogeneic), stem cell source (bone marrow versus
peripheral blood), conditioning regimen (chemotherapy
versus chemotherapy plus total body irradiation), extent of
acute GVHD, sex, and age. In the second model, only
significant predictors were retained. In the event of 1 or
more signiﬁcant (P < .05) categorical predictors, additional
comparisons were conducted to identify the particular cate-
gories responsible for the signiﬁcant effect.
RESULTS
The results for all multidimensional outcome measures are
too lengthy to include in full. Instead, tabulated scores from
the principal QOL and POMS outcomes are shown below,
with summary results from the other questionnaires described
in the text.
Patient Characteristics
Respondents. At the time of BMT, participants were a
mean ± SD of 41.8 ± 11.5 years of age (range, 19-65 years).
The sample was predominantly Caucasian (90%), well edu-
cated (63% with 2-year college degree or higher), and rela-
tively afﬂuent (70% with household income >$30,000), and
the majority (70%) were married.
One year after transplantation, 65% of participants were
employed (full or part time), students, homemakers, or retired.
A total of 32% described themselves as temporarily or perma-
nently disabled, and 12 of the 415 respondents were unem-
ployed and actively seeking work. These proportions changed
substantially in succeeding years. After 2, 3, and 4 years,
respectively, employed, students, homemakers, and retired had
increased to 80%, 80%, and 74% of the sample, whereas those
reporting disability dropped to 18%, 18%, and 20%. Virtually
all respondents had health insurance at all assessment points,
primarily from present or previous employment.
Diagnoses were varied and included chronic leukemias
(31%), acute leukemias (17%), breast cancer (15%), non-
Hodgkin’s lymphomas (14%), and various others (Hodgkin’s
lymphoma, aplastic and refractory anemias, multiple
myeloma, sarcomas, myeloﬁbrosis, etc.) (23%). The major-
ity of patients underwent allogeneic transplantation (67%);
autologous transplantations made up the remaining 33%.
Bone marrow and peripheral blood stem cells constituted
65% and 35% of transplanted hematopoietic cell types,
respectively. Approximately 31% of transplantations were
performed on patients in malignancy remission, with a fur-
ther 31% in relapse, 30% in chronic phase, and the remain-
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ing few (8%) in accelerated phase or blast crisis. At least
25 different preparatory regimens were used, of 2 basic
types: chemotherapy plus radiation (52%) and chemo-
therapy only (48%). Approximately 81% of allogeneic recip-
ients experienced acute GVHD of grade I or higher.
During the first year posttransplantation, medical
records showed that 66% of allogeneic transplantation
patients experienced extensive chronic GVHD; only 2 of
those patients still reported extensive GVHD during their
second year posttransplantation. However, 9 patients with
only limited GVHD during the ﬁrst year developed exten-
sive GVHD in the second year. No extensive GVHD was
reported to develop after the second year.
Nonrespondents. Evaluation of medical records suggested
that at 1 year posttransplantation, respondents (n = 415) and
nonrespondents (n = 264) were similar in demographic, dis-
ease, and treatment characteristics. In univariate compar-
isons, 2 tests of the equality of population distributions
were not significant for sex (P = .30), diagnosis (P = .31),
type of donor (P = .66), remission status (P = .26), marrow
versus blood stem cell transplantation (P = .07), or occur-
rence of acute GVHD (P = .58). Respondents (mean age,
41.8 years) were slightly older (P = .040) than nonrespon-
dents (mean age, 40.7 years), but this was a small age differ-
ence in a population that ranged from 19 to 65. A multivari-
ate logistic regression indicated that prediction of response
was not significant (P = .71) when all discriminators were
considered jointly. Therefore, we judge the year 1 respon-
dents to be representative of the sampled population.
Measurement Characteristics
EORTC QLQ-C30 and BMT Specific Module. Although
the EORTC QLQ-C30 is multidimensional, the dimen-
sions are not strictly independent: the overall score of the
QLQ-C30 in the present study had high internal consis-
tency at each assessment point (Cronbach’s  = 0.8-0.84).
Reliability of subscales at each of the 4 assessment points
were similar. Of the 9 multi-item subscales, 6 were reliable,
with  ranging from 0.71 to 0.95. The 3 remaining sub-
scales indicated questionable reliabilities (Physical Function-
Figure 1. Example of repeated assessments displaying a monotone pattern of missing data. EORTC indicates EORTC (European Organization for
Research and Treatment of Cancer) QLQ-C30 core questionnaire.
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ing = 0.56-0.72, Role Functioning = 0.36-0.47, Nausea/
Vomiting = 0.28-0.65). For the BMT Speciﬁc Module, over-
all internal consistency was also high at each assessment
point (Cronbach’s  = 0.80-0.86), with category  ranging
from 0.7 to 0.91, with 3 exceptions (Skin = 0.52-0.67, Infec-
tions = 0.03-0.41, Fear of Relapse/Dying = 0.48-0.71).
Cronbach’s  for the combined EORTC QLQ-C30 and
BMT Module was between 0.88 and 0.91 at the 4 assess-
ment points. Although the internal consistency reliability
coefficients of a few subscales on the EORTC QLC-C30
and BMT Module were below a criterion for new scales of
0.70 [64], the data from these subscales were cited for nor-
mative comparisons.
Demands of BMT Recovery. Cronbach’s  for the overall
DBMT ranged from 0.88 to 0.9 over the 4 annual assess-
ments. Subscales were reliable, ranging from 0.73 to 0.95,
with the exception of Overall Treatment Issues (0.27-0.76).
Proﬁle of Mood States. Cronbach’s  for the overall POMS
was 0.93 at each assessment point, with subscales ranging
from 0.78 to 0.94.
Ware Health Perception Questionnaire. Cronbach’s  for the
overall WHPQ were between 0.85 and 0.89 over the 4 assess-
ments. Internal consistency of subscales was mixed, with
3 subscales showing acceptable  ranging from 0.81 to 0.93
and 3 others being lower (Prior Health = 0.56-0.67, Health
Worries = 0.63-0.73, and Rejection of Sick Role = 0.15-0.41).
Conditional Analyses
EORTC QLQ-C30 Scores. Table 2 shows the mean scores
and SDs at each assessment time for the QLQ-C30 core
questionnaire. For the 3 global scores (Physical Condition,
QOL, and Health Status), a higher score indicates better
status. Global Health Status combines Global Physical Con-
dition and Global QOL in a single score.
As can be seen in Table 2, the mean values for the indi-
vidual subscales on the QLQ-C30 were all low (<33% of
scale maxima), signifying that the adverse effects of BMT
across subscales of QOL were mild in intensity. Further-
more, a visual examination of the data across successive time
points shows, in many cases, better functioning and less
symptomatology for survivors at later time points. Perceived
Global Physical Condition and QOL were good at the ﬁrst
assessment after transplantation and increased over subse-
quent assessments.
BMT Specific Module
Symptomatology. Table 3 shows the 10 most frequently
reported BMT-specific symptomatology items and cate-
gories from the BMT module, with mean subscale or item
scores (0-100). In each case, a higher mean score represents
a higher reported severity. Although various moderately
severe (defined as scores of 3 or 4 on the 4-point scale),
ongoing BMT-related complications continued for 10% to
30% of the sample over the 4 assessment points, the
reported severity (mean scores) of complications over all
patients was low. Symptom scores on the whole appear rela-
tively stable or improving from 1 year to 4 years post-BMT,
although a few (eg, Skin and Eye Problems) ostensibly show
a slight decremental trend. As a rudimentary and more lib-
eral indication of the overall incidence of BMT-related
symptoms, we also calculated the percentages of patients
reporting the simple occurrence of any of the 17 primary
symptoms on the BMT Module, irrespective of severity.
Virtually all respondents reported the occurrence of at least
1 BMT-related symptom at each annual assessment. The
mean numbers of symptoms reported (of a maximum of 17
possible) were 7.6, 7.2, 7.0, and 6.6 at years 1 through 4,
respectively, although the majority of those symptoms were
rated as mild in severity.
Appearance and Sexual Functioning. At 1 year post-BMT,
13% of survivors reported that they were not at all satisﬁed
with their appearance compared with before BMT. This
number remained relatively constant at 10%, 7%, and 10%
for years 2, 3, and 4, respectively. However, between 17%
and 27% of respondents were not at all satisﬁed with their
Table 2. Conditional Mean Estimates for EORTC QLQ C-30*
Year Posttransplantation
1 (n = 407-411) 2 (n = 216-217) 3 (n = 115-117) 4 (n = 31-35)
Physical Dysfunction 21.7 ± 23.6 17.0 ± 22.9 15.0 ± 22.8 13.1 ± 18.7
Role Dysfunction 27.9 ± 32 20.4 ± 30.7 19.2 ± 29.2 15.7 ± 31.5
Emotional Dysfunction 26.6 ± 21 25.5 ± 20.6 27.8 ± 19.8 30.4 ± 31.5
Cognitive Dysfunction 23.2 ± 23.6 21.9 ± 22.6 25.3 ± 21.7 26.3 ± 21.8
Social Dysfunction 32.5 ± 29 24.2 ± 27.2 22.6 ± 28.1 23.1 ± 29.4
Fatigue 37.1 ± 23.3 33.3 ± 24.2 31.7 ± 22.7 32.6 ± 22.9
Nausea and Vomiting 7.9 ± 13 8.0 ± 14.8 6.1 ± 13.1 5.4 ± 9
Pain 24.4 ± 27.2 22.5 ± 26 24.2 ± 26.2 18.8 ± 22.2
Dyspnea 20.3 ± 23.5 17.8 ± 22.7 15.9 ± 21.7 19.0 ± 20.2
Sleep Disturbance 31 ± 29.7 29.4 ± 29.6 30.4 ± 27.8 40.0 ± 28.9
Appetite Loss 16.6 ± 25.4 12.5 ± 22.5 10.8 ± 19.4 13.3 ± 27.2
Constipation 9.2 ± 18 9.7 ± 20 8.4 ± 18.5 11.8 ± 18.3
Diarrhea 13.9 ± 22.9 15.0 ± 24.6 16.1 ± 24.1 22.5 ± 29
Financial Impact 36.8 ± 34.3 30.7 ± 33.7 24.3 ± 32.5 24.7 ± 29.7
Global Physical Condition† 64 ± 21.9 67.7 ± 23.6 69.8 ± 21.5 69.3 ± 21.1
Global Quality of Life† 70.1 ± 22.6 72.1 ± 23.1 74.8 ± 21 76.3 ± 22.2
Global Health Status† 67 ± 21 69.9 ± 22 72.3 ± 20.2 72.8 ± 20.63
*Data are mean ± SD. Higher dysfunction and symptomatology scores represent poorer functioning or more severe symptoms.
†Higher global scores represent better physical condition, quality of life, and health status.
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Sexual Appeal, Ability to Share Warmth and Intimacy, or
Interest in Sexual Thoughts or Feelings over the 4 assess-
ment points. Most notably, between 41% and 53% of
respondents at each of the 4 yearly assessments revealed that
they had physical problems that reduced their satisfaction
with sex and intimacy.
Overall Health Status/QOL. In years 1 to 4, 63%, 69%,
74%, and 68% of survivors, respectively, rated their Global
Physical Condition as good to excellent (deﬁned as a score
of 5-7 on the original 7-point scale), and 73%, 76%, 81%,
and 80% of survivors assessed their Global QOL as good to
excellent. Only 3.4% (14 of 410 respondents) rated both
their Global QOL and Health Status as poor (a score of ≤2
on the 7-point scale) at 1 year. Similar ﬁgures were evident
for years 2, 3, and 4 (3.1%, 2.6%, and 0%, respectively).
Demands of BMT Recovery. The mean intensity ratings
for all 5 categories of demands (Monitoring Symptoms and
Self, Personal Meaning, Self Image, Social Relationships,
and Treatment Issues) fell between 1 and 2.1 points on the
5-point (0-4) scale. This ﬁnding signiﬁes that the demands
attributed to long-term survival appear to impose little
hardship after BMT. We also estimated the 7 items most
frequently rated as 3 (“quite a bit”) or 4 (“extremely”) for
each assessment point. The 2 demands of BMT most fre-
quently cited by respondents at all 4 assessment points con-
cerned thoughts about the value of life and how to reorder
the priorities of life. More respondents at the first assess-
ment after BMT rated various demands relatively higher
than at later assessments. Other demands consistently rated
highly over all years included qualms about the future of
family, monitoring closely any new symptoms that might
signal a change in health status, difﬁculty in keeping up with
a usual pace or routine, and worries about whether life
would ever return to normal.
A consistent picture emerged when the DBMT was cor-
related with the major QOL outcomes. An inverse relation-
ship existed between DBMT and Global Health Status/
QOL (r = –0.59, P < .01): the higher the intensity of
demands, the lower the perceived QOL/Health Status. Simi-
larly, DBMT correlated positively with the POMS (r = 0.66,
P < .01), implying that the higher the intensity of demands,
the poorer the survivor’s mood adjustment.
Profile of Mood States. Subscale means for the POMS
were uniformly low (<31% of scale maxima) across all
assessment points, indicating relatively good mood and low
psychological distress that was also stable over time. Overall
POMS scores were between 20% and 22% of scale maxima
over the 4 annual assessments.
Mood and level of psychological distress was compared
with published population norms. Compared with norma-
tive samples [60], BMT recipients at years 1 to 4 generally
showed less tension/anxiety (P < .01 to .001, mean PV =
5.4%), less confusion (P < .01 to .001, mean PV = 8.7%),
less depression (P < .05 to .001, mean PV = 3.1%), less
fatigue (P < .05 to .001, mean PV = 1.2%), less anger
(P < .02 to .001, mean PV = 1.7%), and less overall distress
(P < .05 to .001, mean PV = 2.7%). Exceptions included
both males and females at the fourth yearly assessment who
did not differ from norms in rated fatigue or anger, and no
differences from norms in fatigue for females and anger for
males at year 3. There were no differences from norms in
reported vigor at any assessment point except for males at
the year 1 assessment, who reported more vigor (P < .02,
PV = 1.03%).
Overall, as with longer-term BMT survivors in our pre-
vious study [35], respondents between 1 and 4 years post-
transplantation reported less mood disturbance and distress
than the published norms for a nonsymptomatic population.
Ware Health Perceptions Questionnaire. When compared
with normative general population samples [61,62], BMT
survivors at all 4 annual assessments perceived signiﬁcantly
poorer prior health, were more worried about their health,
and felt more susceptible to illness (P < .01 to .001, mean
PV = 10%, range 1.5%-24.5%). Respondents also per-
ceived poorer current health and health outlook in years 1
through 3 (P < .05 to .001, mean PV = 2.4%, range 0.65%-
7.2%). By year 4, however, perceived current health and
health outlook had returned to normal (were not signifi-
cantly different from population norms). Finally, BMT sur-
vivors were no more or less inclined than was the general
population to reject a sick role. Although the health-speciﬁc
worries and perceptions, as reﬂected by the WHPQ, are not
the same as population norms during the early years of
recovery, they do not appear to percolate up to the point
Table 3. Conditional Mean Estimates for the 10 Most Frequently Reported Symptoms From the Bone Marrow Transplantation–Speciﬁc Module*
Year Posttransplantation
1 (n = 272-412) 2 (n = 154-217) 3 (n = 83-117) 4 (n = 20-34)
Skin 13.7 ± 12.5 (22.8) 13.8 ± 14.7 (20.3) 13.8 ± 13.7 (21.7) 14.7 ± 14.7 (30)
Eyes 15.7 ± 18.2 (19.6) 18.1 ± 19.3 (20.8) 20.3 ± 19.4 (26.3) 23.4 ± 19.3 (26.7)
Mouth and Throat 16.5 ± 21.4 (17.6) 12.4 ± 17 (12.1) 9.9 ± 16.3 (7.6) 15 ± 20.1 (16.1)
Painful Joints and Muscles 21.7 ± 24.1 (20.6) 22.8 ± 24.2 (22.2) 23.7 ± 25 (21.9) 17.3 ± 26.9 (17.6)
Cognitive Dysfunction‡ 23.2 ± 23.1 (20.1) 21.6 ± 22.2 (15.9) 23.9 ± 20.7 (20.7) 27.5 ± 21 (19.4)
Chronic GVHD (allogeneic only) 28.5 ± 30.4 (19.9) 25.1 ± 31.7 (18.8) 13.6 ± 24.4 (7.2) 6.6 ± 17.4 (5.0)
Teeth (dental caries) 18.2 ± 27.3 (11.2) 18.1 ± 27.7 (13.1) 17.2 ± 26.5 (12.1) 22.5 ± 30.2 (16.1)
Sinusitis 18.6 ± 27.1 (11.8) 17.8 ± 26.5 (11.9) 15.9 ± 24.6 (9.4) 18.6 ± 24.8 (8.8)
Pulmonary Problems† 9.8 ± 13.1 (8.1) 8.7 ± 11.9 (8.9) 8.1 ± 10.2 (5.9) 11.1 ± 12.6 (8.8)
Fear of Infections/Relapse/Dying 35.3 ± 26.2 (28.9) 27.1 ± 22.5 (18.1) 25 ± 22.6 (16) 21 ± 22.5 (11.8)
*Data are mean ± SD and percentage of responders scoring 3 (quite a bit) or 4 (very much) in parentheses. Higher dysfunction and symptomatol-
ogy scores represent poorer functioning or more severe symptoms. GVHD indicates graft-versus-host disease.
†Subscale means include items from QLQ-C30 core.
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where they affect more general, non–health-speciﬁc moods,
as indexed by the POMS.
Unconditional Analyses
Unconditional estimates for the principal QOL and
POMS subscales are presented in Tables 4 through 6. In
each table, the basic data consist of estimated population
means at years 1, 2, 3, and 4 and their SEs. Estimates of max-
imally discriminating categorical contrasts appear separately
in Tables 4 through 6. QOL measures with no contrast esti-
mates had no signiﬁcant discriminating prognostic factors.
The P values reported for each time effect test the null
hypothesis that the population (or subpopulation) means are
equal across the 4 assessment times. The final columns in
Tables 4 through 6 contain the regression coefﬁcient and SE
for the quantitative predictor age. This estimate is inter-
preted, if significant, as the expected change in the QOL
outcome associated with an increase of 1 year in age.
For ease of interpretation, all variables in Tables 4 through
6 have been linearly transformed as percentages of scale max-
ima, and, with the exception of Overall QOL and Physical
Condition, scales are oriented in the “bad” or “negative”
direction. Thus, a score of 100 generally corresponds to the
worst possible outcome for the scale, whereas a score of 0
denotes the best possible outcome. Although these transfor-
mations achieve an order-of-magnitude comparability among
the diverse measures, they do not yield fully comparable met-
rics. The transformed scales still differ in variability and in
other measurement properties implied by the psychometric
designs of the items composing the scales. Nonetheless, the
means can be compared validly across occasions for each out-
come and very approximately across outcomes.
The unconditional analysis of the major functioning sub-
scales of the QLQ-C30 core displayed in Table 4 shows
signiﬁcant improvement over time for all patients in physi-
cal, role, and social functioning, whereas emotional and cog-
nitive functioning appears relatively stable. Furthermore, in
absolute terms, ratings of severity were consistently below
33% of maximal dysfunction. Physical Dysfunction showed a
significant positive relationship with age, but this effect is
small in absolute terms: each increase of 4 years in age is
associated with an approximately 1% increase in the Physical
Dysfunction mean. Estimates of both Global Physical Con-
dition and Global QOL revealed disease as a signiﬁcant dis-
criminating prognostic factor, with chronic leukemia (CL),
acute leukemia (AL), breast cancer (BC), and non-Hodgkin’s
lymphoma (NHL) as a group differing statistically from
other diagnoses. Although the CL/AL/BC/NHL group
Table 4. Unconditional Mean Estimates and Standard Errors for EORTC QLQ-C30 Core*
Year Posttransplantation
Change Change per Year 
1 2 3 4 Over Time, P of Age ± SE
Physical Dysfunction 21.85 ± 1.16 19.40 ± 1.37 16.10 ± 1.63 13.86 ± 1.89 .0001 0.278 ± 0.10
Role Dysfunction 28.03 ± 1.58 22.82 ± 1.95 19.01 ± 2.26 16.16 ± 4.50 .0002 NS
Emotional Dysfunction 26.63 ± 1.05 25.70 ± 1.31 27.40 ± 1.60 26.79 ± 3.04 .7382 NS
Cognitive Dysfunction 23.35 ± 1.18 22.26 ± 1.41 24.35 ± 1.61 21.65 ± 2.83 .4491 NS
Social Dysfunction 32.56 ± 1.43 25.58 ± 1.65 22.28 ± 2.12 19.20 ± 4.13 .0001 NS
Fatigue
AL + BC 36.34 ± 2.01 32.83 ± 2.77 35.43 ± 3.13 45.88 ± 4.09 .0161 NS
CL + NHL + other 36.96 ± 1.48 33.51 ± 1.92 29.40 ± 2.16 21.42 ± 2.84 .0001 NS
Dyspnea 20.34 ± 1.15 19.10 ± 1.50 15.81 ± 1.81 23.99 ± 2.49 .0074 0.24 ± 0.09
Nausea and Vomiting 7.97 ± 0.65 7.95 ± 0.99 6.28 ± 1.16 5.89 ± 1.53 .3235 NS
Pain
AL + CL + BC + NHL 22.55 ± 1.60 23.53 ± 2.08 25.34 ± 2.57 22.64 ± 3.47 .7175 NS
Other 30.72 ± 2.81 24.28 ± 3.44 29.75 ± 4.39 9.10 ± 5.53 .0020 NS
Sleep Disturbance
BC 39.78 ± 3.44 38.42 ± 3.67 37.86 ± 3.85 44.08 ± 5.17 .4065 NS
AL + CL + NHL + other 28.98 ± 1.64 27.62 ± 2.02 27.06 ± 2.29 33.29 ± 4.08 .4065 NS
Appetite Loss 16.60 ± 1.25 13.05 ± 1.48 10.83 ± 1.71 20.67 ± 3.01 .0001 NS
Constipation
BC 15.85 ± 2.02 16.67 ± 2.28 16.20 ± 2.46 16.34 ± 3.47 .9554 NS
AL + CL + NHL + other 7.89 ± 0.97 8.71 ± 1.41 8.25 ± 1.65 8.38 ± 2.89 .9554 NS
Diarrhea 13.89 ± 1.13 15.09 ± 1.59 15.67 ± 2.04 22.29 ± 4.09 .1914 NS
Financial Impact 36.82 ± 1.68 31.68 ± 2.07 23.98 ± 2.45 20.99 ± 3.52 .0001 –0.36 ± 0.14
Global Physical Condition
CL + AL + BC + NHL 65.59 ± 1.27 66.72 ± 1.84 68.72 ± 1.99 64.28 ± 2.87 .2675 NS
Other 57.54 ± 2.24 64.59 ± 3.08 67.25 ± 3.46 77.77 ± 4.63 .0001 NS
Global Quality of Life
CL + AL + BC + NHL 72.39 ± 1.32 72.86 ± 1.76 75.31 ± 1.96 73.48 ± 3.32 .4766 NS
Other 63.41 ± 2.33 68.44 ± 2.95 71.32 ± 3.43 82.02 ± 5.28 .0021 NS
*Data are mean ± SE. Higher dysfunction and symptomatology scores represent poorer functioning or more severe symptoms. Higher global
scores represent better physical condition and quality of life. NS indicates not signiﬁcant; AL, acute leukemia; BC, breast cancer; CL, chronic
leukemia; NHL, non-Hodgkin’s lymphoma. 
Longitudinal QOL After BMT
585B B & M T
showed stable, unchanging physical condition and QOL over
time, the physical condition and QOL of the other diagnoses
improved significantly over time. However, because all
groups rated physical condition and QOL positively, this dis-
crimination is unlikely to be of clinical prognostic value.
Table 4 also shows the unconditional estimates of the
remaining QLQ-C30 scales and single-item measures. As
with the functioning scales, all measures displayed averages of
low-to-moderate severity ratings, in most cases <40% and
more often <30% of the scale maxima. The analyses did pro-
duce statistically signiﬁcant differences between disease pre-
dictors for 4 measures, but there were no conspicuously high
scores on any measures. Fatigue was signiﬁcantly elevated at
4 years post-BMT for AL and BC but decreased signiﬁcantly
for other disease groups; pain decreased significantly at
4 years for other diagnoses compared with AL/CL/BC/NHL.
Sleep disturbance and constipation appeared to be slightly
higher in BC patients than in others. For all patients, loss of
Table 5. Unconditional Mean Estimates and Standard Errors for Bone Marrow Transplantation–Speciﬁc Module*
Year Posttransplantation
Change Change per Year 
1 2 3 4 Over Time, P of Age ± SE
Overall Skin Problems
AL + BC 21.53 ± 2.07 25.75 ± 3.30 24.32 ± 3.73 51.00 ± 8.14 .0024 NS
CL + NHL + other 22.11 ± 1.53 23.94 ± 2.26 19.13 ± 2.49 16.22 ± 3.90 .0436 NS
Overall Eye Problems 27.33 ± 1.39 29.32 ± 1.97 31.95 ± 2.29 33.77 ± 4.70 .1397 NS
Overall Mouth Problems 23.77 ± 1.39 19.91 ± 1.55 14.40 ± 1.64 20.29 ± 3.37 .0001 NS
Overall Breathing Problems 14.05 ± 1.09 13.84 ± 1.47 10.86 ± 1.72 17.71 ± 2.43 .0803 NS
Overall Pain in Joints
BC 26.06 ± 3.78 28.85 ± 5.05 36.81 ± 7.81 84.59 ± 11.72 .0001 NS
AL + CL + NHL + other 24.96 ± 1.69 27.38 ± 2.19 29.60 ± 2.87 22.06 ± 3.34 .0681 NS
Muscle Pain
BC 24.55 ± 3.66 25.16 ± 4.75 19.16 ± 7.01 60.90 ± 10.54 .0019 NS
AL + CL + NHL + other 24.74 ± 1.62 24.03 ± 2.02 21.92 ± 2.75 15.31 ± 3.44 .0454 NS
Hair Loss
Male 16.68 ± 1.72 22.23 ± 2.23 23.51 ± 2.26 17.20 ± 3.27 .0015 NS
Female 8.42 ± 1.62 13.97 ± 2.15 15.24 ± 2.49 8.94 ± 3.33 .0015 NS
Chronic GVHD 28.52 ± 1.8 25.34 ± 2.4 15.03 ± 2.3 8.41 ± 3.17 .0001 NS
(allogeneic only)
Nail Loss 2.76 ± 0.59 3.52 ± 0.87 2.87 ± 0.86 4.80 ± 2.30 .6927 NS
Teeth Problems 18.75 ± 1.37 19.23 ± 1.79 18.75 ± 2.28 24.28 ± 4.73 .6755 NS
Abnormal Sense of Taste 18.44 ± 1.38 13.35 ± 1.37 10.27 ± 1.65 9.46 ± 3.43 .0001 0.24 ± 0.09
Abdominal Pain 13.77 ± 0.99 16.12 ± 1.47 12.07 ± 1.59 11.30 ± 2.38 .0740 NS
Weight Loss 7.10 ± 0.82 7.35 ± 1.17 6.17 ± 1.20 2.70 ± 2.10 .2366 NS
Sexual Dissatisfaction Items
BC 62.88 ± 3.22 59.73 ± 3.41 59.72 ± 3.58 67.16 ± 4.91 .0631 NS
AL + CL + NHL + other 51.78 ± 1.51 48.62 ± 1.87 48.61 ± 2.12 56.05 ± 3.89 .0631 NS
*Data are mean ± SE. Higher dysfunction and symptomatology scores represent poorer functioning or more severe symptoms. AL indicates
acute leukemia; BC, breast cancer; NS, not signiﬁcant; CL, chronic leukemia; NHL, non-Hodgkin’s lymphoma; GVHD, graft-versus-host disease. 
Table 6. Unconditional Mean Estimates and Standard Errors for Proﬁle of Mood Status Subscales* 
Year Posttransplantation
Change Change per Year 
1 2 3 4 Over Time, P of Age ± SE
Tension/Anxiety 25.26 ± 0.97 23.92 ± 1.20 26.96 ± 1.43 21.14 ± 2.03 .1671 NS
Depression/Dejection 14.60 ± 0.86 14.91 ± 0.98 14.51 ± 1.29 12.48 ± 1.50 .3838 NS
Anger/Hostility 14.33 ± 0.80 14.39 ± 0.98 15.56 ± 1.30 13.27 ± 1.95 .5421 –0.22 ± 0.07
Lack of Vigor/Inactivity
AL + CL + BC 51.04 ± 1.35 50.51 ± 1.83 54.03 ± 2.11 57.65 ± 3.77 .0838 NS
NHL + other 53.94 ± 1.76 51.11 ± 2.31 47.48 ± 2.70 39.01 ± 4.19 .0012 NS
Fatigue/Inertia
BC 31.42 ± 3.09 31.81 ± 3.95 46.45 ± 4.87 62.36 ± 8.65 .0001 NS
AL + CL + NHL + other 30.47 ± 1.39 29.09 ± 1.71 29.12 ± 1.97 26.29 ± 2.78 .4210 NS
Total Mood Disturbance 24.39 ± 0.78 23.99 ± 0.92 24.31 ± 1.16 22.21 ± 1.45 .3460 NS
*Data are mean ± SE. All scores were linearly transformed as percentages of scale maxima (0-100). NS indicates not significant; AL, acute
leukemia; CL, chronic leukemia; BC, breast cancer; NHL, non-Hodgkin’s lymphoma. 
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appetite increased and ﬁnancial impact decreased signiﬁcantly
over time. Generally, scores remained low and within a rela-
tively small range over time. Figures 2, 3, and 4 respectively
show mean dysfunction for the primary EORTC QLQ-C30
functioning scales, mean positive function for the 2 global
health status scales, and mean dysfunction for 2 representa-
tive single-item measures. These ﬁgures show quite vividly
the apparent stability of QOL measures over time and the
relatively low ratings of severity on the 0-to-100 scales. In
Figures 3 and 4, in particular, it can be seen clearly that dif-
ferences shown between disease groups, although statistically
signiﬁcant, are clinically unremarkable.
Table 5 displays the unconditional estimates for BMT-
related symptoms and side effects from the BMT Module.
Again, with few exceptions, mean scores are low to moder-
ate, on the order of 30% of scale maxima or less, across
measures and time points. Of all symptoms, average scores
across all 4 time points were highest for sexual dissatisfac-
tion, although the range (48%-67% of scale maxima) indi-
cated only moderate rather than extreme dissatisfaction with
Sexual Appeal, Ability to Share Warmth and Intimacy, or
Interest in Sexual Thoughts or Feelings. BC patients gener-
ally appeared less satisfied with sexual issues than other
patients. Three symptom measures were rated conspicu-
ously highly at year 4 relative to other annual assessment
points. BC patients reported moderately high levels of mus-
cle pain and very high levels of joint pain at year 4 compared
with other disease groups and previous assessment points,
Figure 2. Unconditional estimates of mean dysfunction for selected EORTC  QLQ-C30 core quality-of-life functioning scales.
Figure 3. Unconditional estimates of mean function in the EORTC QLQ-C30 Global Quality of Life (QOL) and Physical Condition (PC) scales.
CL indicates chronic leukemia; AL, acute leukemia; BC, breast cancer; NHL, non-Hodgkin’s lymphoma.
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but the SEs for these estimates are rather large. AL and
BC patients reported moderately severe skin problems at
year 4 compared with other groups and previous years. In
all other respects, however, these disease subgroups were
typical of patients overall. Figures 5 and 6 display uncon-
ditional estimates for selected scales and items from the
BMT Module. As with Figures 2 through 4, Figure 5 illus-
trates well the generally low severity and lack of change
over time of typical scale and item scores. Although the
relative separation of the 3 scales/items in Figure 5 is
slightly more pronounced than in Figures 2 and 3, the
absolute levels of rated severity are even lower. The
significant distinctions described above between disease
groups at year 4 can be seen more easily in Figure 6.
Finally, Table 6 shows unconditional estimates of sub-
scales and total mood disturbance from the POMS. AL, CL,
and BC patients reported ongoing lack of vigor, whereas
lymphoma and other patients reported signiﬁcantly increas-
ing levels of activity over time. BC patients also perceived
signiﬁcantly higher levels of fatigue over time, especially in
year 4, compared with the rest of the sample. Otherwise,
mood and psychological disturbance did not change over
time but remained at a relatively constant and low level. Fig-
ure 7 displays unconditional estimates for overall mood dis-
turbance and lack of vigor. 
DISCUSSION
These data from a large cohort of BMT survivors con-
ﬁrm and further elaborate on the ﬁndings of smaller-scale
studies in the literature. Typical survivors were doing well
and were either stable or improving over time on most
measures of QOL, functioning, and severity of late compli-
cations. Reported disability dropped after the ﬁrst year, and
most respondents appeared to be leading active and pro-
ductive lives. Although nearly all respondents reported the
existence of 1 or more BMT-related symptoms, the rated
severity of these was consistently low to moderate. On a few
measures (eg, emotional dysfunction, skin and eye problems,
chronic GVHD, sleep disturbance), rated severities were
slightly elevated at year 4, although still relatively low on
the 0-to-100 scale. As with a number of previous studies, the
POMS showed respondents to have good mood and low
psychological distress, in most cases better than population
norms for healthy people. Perceived overall physical condi-
tion and QOL was high at 1 year after transplantation and
became even better over time.
Reports of sexual dysfunction were not uncommon
among our study patients. Between one ﬁfth and one quar-
ter of our sample were dissatisﬁed with their sexual appeal,
ability to share warmth and intimacy, or interest in sexual
thoughts or feelings, and approximately one half perceived
physical problems that reduced their satisfaction with sex
and intimacy. These ﬁgures are very similar to our own pre-
vious study with extreme long-term survivors [35] and con-
ﬁrm the ﬁndings of other publications [25,28,30,65-67] that
impairment in sexual functioning and problems with psy-
chosexual sequelae may be common after intensive chemo-
therapy or radiochemotherapy.
Results from the DBMT suggested that, from the outset,
survivors were most focused on the big picture rather than on
the minutiae of illness and recovery and that this emphasis on
global demands continued through year 4. Patients were most
often concerned about the overall value and priorities of life,
and to a lesser extent about the uncertainties of the future.
Speciﬁc illness worries cannot entirely be dismissed, however.
The WHPQ showed that BMT survivors at all 4 annual
assessments were more worried about their health and felt
more susceptible to illness than population norms. Respon-
dents also perceived poorer current health and health outlook
in years 1 to 3. By year 4, however, perceived current health
and health outlook had returned to normal.
Overall, our descriptive conditional analyses paint an
encouraging picture of a post-BMT life of high quality.
Figure 4. Unconditional estimates of mean dysfunction in selected EORTC QLQ-C30 core symptoms. AL indicates acute leukemia; BC, breast
cancer; CL, chronic leukemia; NHL, non-Hodgkin’s lymphoma; OTH, other.
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Although a number of relatively mild complications persist,
and a few divergent scores at the year 4 assessment identify
potential trouble spots, QOL appears not to decline overall
and may even improve over time for surviving, compliant
patients. These results are important because they predict
the QOL that well-motivated survivors can expect to
experience, on average. However, follow-up subsamples of
well-motivated survivors may not be representative of the
original sample and newly accruing patients. Our year-4
assessment, for example, comprised just 35 of the original
415 year-1 respondents (ie, only 35 from our year-1 group
had yet reached their fourth anniversaries and had responded).
Without additional information, it would be extremely haz-
ardous to generalize to new patients from such a restricted
subsample. Fortunately, our unconditional estimates based
on a likelihood criterion incorporate a very important
source of additional information: the prior data and the cor-
relations between assessments. This information, considered
jointly, allows strengthened estimation of the population
trends at all 4 assessments, with the SEs accurately convey-
ing the degree of uncertainty at each assessment point.
Because the unconditional estimates are not dependent on a
possibly filtered or rarefied subsample, they largely avoid
any induced positive (optimistic) bias. It is thus crucial to
confirm any impression of positive response suggested by
the descriptive conditional analyses with the less biased
unconditional estimates. If the same pattern of positive
response is also seen with the unconditional estimates, then
it is much more likely that the trend is genuine and not an
artifact of sampling or attrition.
Figure 5. Unconditional estimates of mean dysfunction in selected symptoms from the Bone Marrow Transplantation–Speciﬁc Module.
Figure 6. Unconditional estimates of mean dysfunction in selected symptoms by diagnostic profile from the Bone Marrow Transplantation–
Specific Module.
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Our unconditional estimates broadly confirm our
impression from the conditional descriptive data that, in
absolute terms, patients are doing well up to 4 years after
transplantation. Patients showed significant improvements
over the 4 annual assessments in various measures of func-
tioning from the QLQ-C30, and no decrement in the
remainder. Global physical condition and QOL were high
from year 1 and remained high or even increased over sub-
sequent assessments. The majority of other symptom, side
effect, and psychological dysfunction scores also were con-
sistently low, mostly less than 30% of the maximum possible
dysfunction or severity. As with conditional analyses, the
unconditional data highlighted the relative prevalence of
concerns about psychosexual functioning.
In some cases, prognostic factors are relevant. Despite
the emphasis in the literature on evaluating QOL as a func-
tion of type of transplant received, our results, based on
large samples, showed no dependence of any outcome on
type of transplant, source of transplant, or conditioning
regimen. Age was statistically significant for a few out-
comes, but these associations were small in practical terms.
The most important prognostic factor was diagnosis. For
certain outcomes, significant differences may not be clini-
cally important. For example, BC patients had signiﬁcantly
worse constipation than the other diagnostic groups, but
the difference was small; all diagnoses had minimal dys-
function in absolute terms (8%-16% of scale maxima). For
1 or 2 specific outcomes, however, the results indicated
clear and important differences. For example, although
they did well in most other respects, BC patients developed
quite serious pain in joints and, to a lesser extent, muscles
in the fourth year posttransplantation. Estimates were
significantly worse than for other diagnoses by objective
statistical criteria and clearly merit further clinical investi-
gation. These results should be interpreted cautiously, how-
ever. Despite statistical signiﬁcance of the effect, only 3 of
the BC patients in our sample had reached the 4-year
anniversary of their BMT and completed the year-4 assess-
ment at time of analysis, so the confidence intervals for
these results are quite wide. The best estimate, in this
instance, must remain imprecise until more patients can be
measured at the later assessments. In more global terms, it
is important to place these BC data in context. With the
exception of their markedly high joint and muscle pain and
much less noteworthy year-4 increases in a few other meas-
ures, BC patients otherwise were largely typical of the rest
of the sample in functioning and other primary outcomes
and, like the rest of the sample, reported good physical
condition and QOL. Although showing significant differ-
ences on individual scales or items from our extensive
battery, no single disease or combination of diseases was
predictive of a wide range of QOL outcomes: no disease
group had poorer QOL over the entire spectrum.
The data reported in this article primarily describe esti-
mates of population means. Although these means gener-
ally indicate healthy status and functioning for typical
members of the population, it must be remembered that
many members of this population are not typical: some
have functioning and status far worse than the mean, and
some do much better. Multivariate analysis indicates that, at
each occasion, several patients have patterns of responses
more extreme than would be expected in chance sampling
from a multivariate normal distribution. It is unfortunate
that, so often in summaries of descriptive studies, means
and SEs are regarded as the principal results, but SDs are
considered of little interest. Positive mean findings must
not obscure the reality that many individual patients suffer
severe QOL impact.
From our review of the literature, we suggested that
the general consensus is that survivors of BMT report rela-
tively good QOL that improves over time but also includes
a variety of residual difficulties. We believe that the pres-
ent study definitively confirms that conclusion over a
4-year posttransplantation period with a very large patient
Figure 7. Unconditional estimates of mean dysfunction in selected scales from the Proﬁle of Mood States. AL indicates acute leukemia; CL,
chronic leukemia; BC, breast cancer; NHL, non-Hodgkin’s lymphoma; OTH, other. 
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cohort and a comprehensive battery of QOL measures.
Although some studies [21,24] have tentatively identified
risk factors, such as type of transplant, conditioning regi-
men, age, and social support, for later deficits in QOL
after BMT we found little evidence of any prognostic fac-
tors except diagnosis and age. Furthermore, with very few
exceptions, diagnosis as a factor merely appears to distin-
guish those patients who have mild complications from
other patients who have even milder complications.
Whereas conventional analyses might be positively biased
by self-selection, especially in later annual assessments, our
unconditional estimates should be relatively immune to
this artifact. A minority of our patients do continue to
report some disability up to 4 years after transplantation.
Although this does not appear to pose a subjective burden
on the patients themselves, we must not dismiss the wider
impact of disability on family and society. However, the
fact that we find similarly good trends with both condi-
tional and unconditional estimates suggests that most
patients really are doing well after BMT.
REFERENCES
1. Sullivan KM. Longterm followup and quality of life after hemato-
poietic stem cell transplantation. J Rheumatol Suppl. 1997;24:46-52.
2. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host
disease and other late complications of bone marrow transplanta-
tion. Semin Hematol. 1991;28:250-259.
3. Sullivan KM, Storb R. Bone marrow transplantation and graft-
versus-host disease. In: Brent L, Sells R, eds. Organ Transplantation:
Current Clinical and Immunological Concepts. London: Bailliere Tin-
dall; 1989:91-118.
4. Applebaum FR, Thomas ED. Treatment of acute leukemia in
adults with chemoradiotherapy and bone marrow transplantation.
Cancer. 1985;55:2202-2209.
5. Buchsel PC. Long-term complications of allogeneic bone marrow
transplantation: nursing implications. Oncol Nurs Forum. 1986;
13:61-70.
6. Nims JW, Strom S. Late complications of bone marrow transplant
recipients: nursing care issues. Semin Oncol Nurs. 1988;4:47-54.
7. Press OW, Schaller RT, Thomas ED. Bone marrow transplant
complications. In: Toledo-Pereyra LH, ed. Complications of Organ
Transplantation. New York: Marcel Dekker; 1989;399-424. 
8. Sullivan KM, Storb R, Buchner CD, et al. Graft-versus-host disease
as adoptive immunotherapy in patients with advanced hematologic
neoplasms. N Engl J Med. 1989;320:828-834.
9. Osoba D. Lessons learned from measuring health-related quality of
life in oncology. J Clin Oncol. 1994;12:608-616. 
10. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr,
Crowley J. Quality of life endpoints in cancer clinical trials: review
and recommendations. J Natl Cancer Inst. 1989;81:485-495. 
11. Aaronson NK. Methodological issues in psychosocial oncology
with special reference to clinical trials. In: Ventafridda V, van Dam
FSAM, Yancik R, Tamburini M, eds. Assessment of Quality of Life
and Cancer Treatment. Amsterdam: Excerpta Medica; 1986:29-41. 
12. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related
quality of life. Ann Intern Med. 1993;118:622-629. 
13. Aaronson NK. Quality of life: what is it? How should it be meas-
ured? Oncology. 1988;2:69-76. 
14. Winer EP, Sutton LM. Quality of life after bone marrow trans-
plantation. Oncology. 1994;8:19-27. 
15. Nayfield SG, Gantz PA, Moinpour CM, Cella DF, Hailey BJ.
Report from a National Cancer Institute (USA) Workshop on
Quality of Life Assessment in Cancer Clinical Trials. Qual Life Res.
1992;1:203-210. 
16. Tchekmedyian NS, Cella DS. Quality of Life in Oncology Practice and
Research. New York: Dominus Publishing; 1991.
17. Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM,
Fields KK. Quality of life following bone marrow transplantation
for breast cancer: a comparative study. Bone Marrow Transplant.
1997;19:257-264.
18. Molassiotis A, van den Akker OBA, Milligan DW, et al. Quality of
life in long-term survivors of marrow transplantation: comparison
with a matched group receiving maintenance chemotherapy. Bone
Marrow Transplant. 1996;17:249-258.
19. Prieto JM, Saez R, Carreras E, et al. Physical and psychosocial
functioning of 117 survivors of bone marrow transplantation. Bone
Marrow Transplant. 1996;17:1133-1142.
20. Andrykowski MA, Bruehl S, Brady MJ, Henslee-Downey PJ. Phys-
ical and psychosocial status of adults one-year after bone marrow
transplantation: a prospective study. Bone Marrow Transplant.
1995;15:837-844.
21. Andrykowski MA, Greiner CB, Altmaier EM, et al. Quality of life
following bone marrow transplantation: ﬁndings from a multicen-
tre study. Br J Cancer. 1995;71:1322-1329. 
22. Andrykowski MA, Carpenter JS, Greiner CB, et al. Energy level
and sleep quality following bone marrow transplantation. Bone
Marrow Transplant. 1997;20:669-679.
23. Fromm K, Andrykowski MA, Hunt J. Positive and negative psy-
chosocial sequelae of bone marrow transplantation: implications for
quality of life assessment. J Behav Med. 1996;19:221-240.
24. Baker F, Wingard JR, Curbow B, et al. Quality of life of bone mar-
row transplant long-term survivors. Bone Marrow Transplant.
1994;13:589-596.
25. Hengeveld MW, Houtman RB, Zwaan FE. Psychological aspects
of bone marrow transplantation: a retrospective study of 17 long-
term survivors. Bone Marrow Transplant. 1988;3:69-75. 
26. Chao NJ, Tierney DK, Bloom JR, et al. Dynamic assessment of
quality of life after autologous bone marrow transplantation. Blood.
1992;80:825-830. 
27. Wingard JR, Curbow B, Baker F, Piantadosi S. Health, functional
status, and employment of adult survivors of bone marrow trans-
plantation. Ann Intern Med. 1991;114:113-115. 
28. Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan
KM. Recovery after allogeneic marrow transplantation: prospective
study of predictors of long-term physical and psychosocial func-
tioning. Bone Marrow Transplant. 1993;11:319-327. 
29. Wolcott DL, Wellisch DK, Fawzy FI, Landsverk J. Adaptation of
adult bone marrow transplant recipient long-term survivors. Trans-
plantation. 1986;41:478-484. 
30. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with
acute myelogenous leukemia in prolonged ﬁrst complete remission
after bone marrow transplantation (allogeneic or autologous) or
chemotherapy: a cross-sectional study of the EORTC-GIMEMA
AML 8A trial. Bone Marrow Transplant. 1997;20:307-315. 
31. Whedon M, Stearns D, Mills LE. Quality of life of long-term adult
survivors of autologous bone marrow transplantation. Oncol Nurs
Forum. 1995;22:1527-1535. 
32. Sutherland HJ, Fyles GM, Adams G, et al. Quality of life fol-
lowing bone marrow transplantation: a comparison of patient
reports with population norms. Bone Marrow Transplant.
1997;19:1129-1136.
Longitudinal QOL After BMT
591B B & M T
33. McQuellon RP, Craven B, Russell GB, et al. Quality of life in
breast cancer patients before and after autologous bone marrow
transplantation. Bone Marrow Transplant. 1996;18:579-584. 
34. Molassiotis A, Boughton BJ, Burgoyne T, van den Akker OBA.
Comparison of the overall quality of life in 50 long-term survivors
of autologous and allogeneic bone marrow transplantation. J Adv
Nurs. 1995;22:509-516. 
35. Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of
life of 125 adults surviving 6-18 years after bone marrow transplan-
tation. Soc Sci Med. 1995;40:479-490. 
36. Haberman M, Bush NE, Young K, Sullivan KM. Quality of life of
adult long-term survivors of bone marrow transplantation: a qualita-
tive analysis of narrative data. Oncol Nurs Forum. 1993;20:1545-1553. 
37. Hjermstad MJ, Evensen S, Kvaloy S, Fayers PM, Kaasa S. Health-
related quality of life 1 year after allogeneic or autologous stem-cell
transplantation: a prospective study. J Clin Oncol. 1999;17:706-718. 
38. Neitzert CS, Ritvo P, Dancey J, Weiser K, Murray C, Avery J. The
psychosocial impact of bone marrow transplantation: a review of
the literature. Bone Marrow Transplant. 1998;22:409-422. 
39. Kopp M, Schweigkoﬂer H, Holzner B, et al. Time after bone mar-
row transplantation as an important variable for quality of life:
results of a cross-sectional investigation using two different instru-
ments for quality-of-life assessment. Ann Hematol. 1998;77:27-32. 
40. Curran D, Bacchi M, Schmitz SF, Molenberghs G, Sylvester RJ.
Identifying the types of missingness in quality of life data from clin-
ical trials. Stat Med. 1998;17:739-756. 
41. Fairclough DL, Peterson HF, Chang V. Why are missing quality
of life data a problem in clinical trials of cancer therapy? Stat Med.
1998;17:667-677.
42. Hoeymans N, Feskens EJ, Van Den Bos GA, Kromhout D. Non-
response bias in a study of cardiovascular diseases, functional sta-
tus and self-rated health among elderly men. Age Ageing.
1998;27:35-40. 
43. Zwinderman AH. Statistical analysis of longitudinal quality of life
data with missing measurements. Qual Life Res. 1992;1:219-224. 
44. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to
quality-of-life assessment in cancer clinical trials. Recent Results Can-
cer Res. 1988;111:231-249. 
45. Aaronson NK, Bakker W, Stewart AL, van Dam FSAM, van Zand-
wijk N, Yarnold JR: Multidimensional approach to the measure-
ment of quality of life in lung cancer clinical trials. In: Aaronson
NK, Beckman J, eds. The Quality of Life of Cancer Patients. New
York: Raven Press; 1987:63-82. 
46. Aaronson NK, Ahmedzai S, Bergman B, et al. The European
Organization for Research and Treatment of Cancer QLQ-C30: a
quality-of-life instrument for use in international clinical trials in
oncology. J Natl Cancer Inst. 1993;85:365-376. 
47. Watson M, Zittoun R, Hall E, Solbu G, Wheatley K. A modular
questionnaire for the assessment of longterm quality of life in
leukaemia patients: the MRC/EORTC-LEU. Qual Life Res.
1996;5:15-19. 
48. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The
EORTC QLQ-LC13: a modular supplement to the EORTC core
quality of life questionnaire (QLQ-C30) for use in lung cancer clin-
ical trials. Eur J Cancer. 1994;30:635-642. 
49. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the
European Organization for Research and Treatment of Cancer Core
Quality-of-Life Questionnaire. J Clin Oncol. 1995;13:1249-1254. 
50. Ringdal GI, Ringdal K. Testing the EORTC quality of life ques-
tionnaire on cancer patients with heterogeneous diagnoses. Qual
Life Res. 1993;2:129-140. 
51. Mercier M, Bonneterre J, Schraub S, Lecomte S, el Hasnaoui A.
The development of a French version of a questionnaire on the
quality of life in cancerology (Functional Living Index-Cancer:
FLIC). Bull Cancer. 1998;85:180-186. 
52. Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaron-
son NK. The European Organization for Research and Treatment
of Cancer approach to developing questionnaire modules: an
update and overview: EORTC Quality of Life Study Group. Qual
Life Res. 1998;7:291-300. 
53. Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF.
Responsiveness to change in health-related quality of life in a ran-
domized clinical trial: a comparison of the Prostate Cancer Speciﬁc
Quality of Life Instrument (PROSQOLI) with analogous scales
from the EORTC QLQ-C30 and a trial speciﬁc module: European
Organization for Research and Treatment of Cancer. J Clin Epi-
demiol. 1998;51:137-145. 
54. Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A. Modiﬁca-
tion of the EORTC QLQ-C30 (version 2.0) based on content
validity and reliability testing in large samples of patients with can-
cer: the Study Group on Quality of Life of the EORTC and the
Symptom Control and Quality of Life Committees of the NCI of
Canada Clinical Trials Group. Qual Life Res. 1997;6:103-108. 
55. Klee M, Groenvold M, Machin D. Quality of life of Danish
women: population-based norms of the EORTC QLQ-C30. Qual
Life Res. 1997;6:27-34. 
56. Carlsson M, Hamrin E. Measurement of quality of life in women
with breast cancer: development of a Life Satisfaction Question-
naire (LSQ-32) and a comparison with the EORTC QLQ-C30.
Qual Life Res. 1996;5:265-274. 
57. Borghede G, Sullivan M. Measurement of quality of life in local-
ized prostatic cancer patients treated with radiotherapy: develop-
ment of a prostate cancer-specific module supplementing the
EORTC QLQ-C30. Qual Life Res. 1996;5:212-222. 
58. Osoba D, Aaronson NK, Muller M, et al. The development and
psychometric validation of a brain cancer quality-of-life question-
naire for use in combination with general cancer-speciﬁc question-
naires. Qual Life Res. 1996;5:139-150.
59. Haberman M, Woods N, Packard N. Demands of chronic illness:
reliability and validity assessment of a demands-of-illness inventory.
Holist Nurs Pract. 1990;5:25-35. 
60. McNair DM, Lorr M, Droppelman LF. EDITS Manual for the Pro-
ﬁle of Mood States. San Diego, CA: Educational and Industrial Test-
ing Service; 1971.
61. Ware JE. Scales for measuring general health perception. Health
Serv Res. 1976;11:396-415. 
62. Ware JE, Snyder MK, Wright WR. Development and Validation
Scales to Measure Patient Satisfaction With Health Care Services. Car-
bondale, IL: Southern Illinois University; 1976.
63. Little RJA, Rubin DB. Statistical Analyses With Missing Data. New
York: Wiley and Sons; 1987.
64. Nunnally JC. Psychometric Theory. 2nd ed. New York: McGraw-
Hill; 1978.
65. Syrjala KL, Roth-Roemer SL, Abrams JR, et al. Prevalence and
predictors of sexual dysfunction in long-term survivors of marrow
transplantation. J Clin Oncol. 1998;16:3148-3157. 
66. Schmidt G, Fonbuena P, Chao N. Quality of life in survivors of
allogeneic BMT for malignant disease [abstract]. Proc Am Soc Clin
Oncol. 1989;18:311.
67. Wingard JR, Curbow B, Baker F, Zabora J, Piantadosi S. Sexual
satisfaction in survivors of bone marrow transplantation. Bone Mar-
row Transplant. 1992;9:185-190.
